Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (201-210 of 272) with videos related to

Pageof 28
Sort By:
Advances in Therapy|August 28, 2025
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel DiseaseGerd R Burmester, Atul Deodhar, Alan D Irvine, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
RMD Open|June 4, 2024
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studiesMaureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, et al.
ACR Open Rheumatology|May 15, 2024
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 TrialFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
Lancet (London, England)|March 18, 2020
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trialAtul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Annals of the Rheumatic Diseases|March 16, 2011
Predicting the outcome of ankylosing spondylitis therapyNathan Vastesaeger, Désirée van der Heijde, Robert D Inman, et al.
The Journal of Rheumatology|July 15, 2024
Advances in Psoriatic Disease Research: Insights From GRAPPA Pilot Research AwardeesAshley Elliott, Tejpal Gill, Jaehwan Kim, et al.
RMD Open|July 16, 2020
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II studyPhilip J Mease, Dafna D Gladman, Atul Deodhar, et al.
Arthritis and Rheumatism|August 1, 2009
Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximabJürgen Braun, Désirée van der Heijde, Mittie K Doyle, et al.
Pageof 28

Showing results (201-210 of 272) with videos related to

Sort By:
Pageof 28
Advances in Therapy|August 28, 2025
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel DiseaseGerd R Burmester, Atul Deodhar, Alan D Irvine, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
RMD Open|June 4, 2024
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studiesMaureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, et al.
ACR Open Rheumatology|May 15, 2024
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 TrialFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
Lancet (London, England)|March 18, 2020
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trialAtul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Annals of the Rheumatic Diseases|March 16, 2011
Predicting the outcome of ankylosing spondylitis therapyNathan Vastesaeger, Désirée van der Heijde, Robert D Inman, et al.
The Journal of Rheumatology|July 15, 2024
Advances in Psoriatic Disease Research: Insights From GRAPPA Pilot Research AwardeesAshley Elliott, Tejpal Gill, Jaehwan Kim, et al.
RMD Open|July 16, 2020
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II studyPhilip J Mease, Dafna D Gladman, Atul Deodhar, et al.
Arthritis and Rheumatism|August 1, 2009
Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximabJürgen Braun, Désirée van der Heijde, Mittie K Doyle, et al.
Pageof 28